Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2024-07-26 Regulatory Filings
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
Regulatory Filings Classification · 95% confidence The document is a press release from Xspray Pharma AB announcing that they received a Complete Response Letter (CRL) from the FDA regarding their New Drug Application (NDA) for Dasynoc. It details the FDA's requests (labeling comprehension and manufacturing site inspection) and the company's response, including a delay in the anticipated launch. The text concludes with a statement that this information is made public pursuant to the EU Market Abuse Regulation and includes an attachment link. This type of announcement, detailing significant regulatory feedback or operational updates that are material to investors but do not fit neatly into standard financial reports (like 10-K, ER, or IR), is best classified as a general Regulatory Filing or Announcement. Since it is not a specific financial report, a management change, or a dividend notice, the most appropriate general category is Regulatory Filings (RNS), as it serves as a broad disclosure mechanism for material, non-standard news under market abuse rules. The document length is moderate, but its primary function is regulatory disclosure of a specific event, not the publication of a full report itself.
2024-07-26 English
Xspray Pharmas studie på XS003 visar matchande biotillgänglighet vid mer än 50% lägre dos än Tasigna
Report Publication Announcement Classification · 98% confidence The document is a press release dated July 9, 2024, announcing new clinical data regarding the product candidate XS003, specifically mentioning matching bioavailability compared to Tasigna at a lower dose. It discusses clinical progress, regulatory filing timelines (FDA submission in H1 2025), and includes contact information and a boilerplate description of the company. Crucially, the end of the document contains a section titled "Bifogade filer" (Attached files) with a link to a PDF, and the document length is relatively short (4477 characters). This structure strongly indicates an announcement about the release of information or results, rather than the full, comprehensive report itself (like an IR or 10-K). Since it is a formal announcement of a significant event/update, and it points to an attached file, it fits best under Report Publication Announcement (RPA) or potentially Regulatory Filing (RNS) if RPA wasn't available. Given the explicit mention of publishing information and linking to the source material, RPA is the most precise fit.
2024-07-09 Swedish
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose
Regulatory Filings Classification · 95% confidence The document is a press release dated July 9, 2024, announcing new clinical data regarding the company's product candidate XS003, including bioavailability matching Tasigna at a lower dose. It discusses clinical progress, regulatory submission timelines (FDA in H1 2025), and includes boilerplate information about the company and contact details. Crucially, the end of the document states: "This information is information that Xspray Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation." This structure—a brief announcement of material news with a publication timestamp—is characteristic of a general regulatory filing or press release mandated by market regulations, rather than a comprehensive financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a mandatory disclosure of material, non-financial operational/clinical news under EU regulation, and it doesn't fit the specific categories like Capital Update (CAP) or Legal Report (LTR), the most appropriate general category for mandatory regulatory disclosures that don't fit elsewhere is Regulatory Filings (RNS). The document length (3902 chars) is short, suggesting it is the announcement itself, not the full underlying study report.
2024-07-09 English
New number of shares and votes in Xspray Pharma after TO6
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a change in the number of shares and votes following the subscription of warrants (TO6). It details the increase in outstanding shares and the corresponding increase in share capital. This directly relates to a change in the company's capital structure due to the exercise of options/warrants, which falls under the definition of 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core content is the capital change itself, not just the announcement of a report, making SHA a better fit than RPA or RNS. The document is short (1791 chars) but the subject matter is a definitive capital structure event.
2024-05-31 English
Nytt antal aktier och röster i Xspray Pharma efter TO6
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (2265 characters) from Xspray Pharma AB regarding a change in the total number of shares and votes following the exercise of warrants (TO6). It explicitly states that new shares have been issued and registered. This type of announcement, detailing a change in the number of outstanding shares due to capital structure events (like warrant exercise leading to new share issuance), directly corresponds to the 'Share Issue/Capital Change' category. Although it is a regulatory filing, the specific nature of the change points more precisely to SHA than the general RNS fallback. It is not an announcement of a report (RPA) as it contains the core information itself, not just a link to an attached report.
2024-05-31 Swedish
Kommuniké från årsstämma i Xspray Pharma AB (publ) 21 maj 2024
AGM Information Classification · 99% confidence The document is explicitly titled "Kommuniké från årsstämma i Xspray Pharma AB (publ) 21 maj 2024" which translates to "Communiqué from the Annual General Meeting in Xspray Pharma AB (publ) May 21, 2024". The content details decisions made at the AGM, including the approval of the 2023 financial statements, discharge of the board, dividend decision, election of board members and auditor, approval of remuneration reports, and authorization for share issuance. These are all core activities of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information). The document length is relatively short (4928 chars) and appears to be a summary/press release of the meeting outcomes, fitting the 'AGM-R' category better than a full regulatory filing like 10-K or IR.
2024-05-21 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.